✦ LIBER ✦

Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa

✍ Scribed by David Marin; Sarah Marktel; Richard Szydlo; John P Klein; Marco Bua; Nicola Foot; Eduardo Olavarria; Pat Shepherd; Edward Kanfer; John M Goldman; Jane F Apperley

Book ID: 117284398
Publisher: The Lancet
Year: 2003
Tongue: English
Weight: 126 KB
Volume: 362
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(03)14182-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prognostic factors for patients with chr

Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa

✍ Marin, D; Marktel, S; Bua, M; Szydlo, R M; Franceschino, A; Nathan, I; Foot, N; 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 123 KB

Effects of imatinib and interferon on pr

Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors

✍ Greg R. Angstreich; William Matsui; Carol Ann Huff; Milada S. Vala; James Barber 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 179 KB

Impact of BCR-ABL mutations on response

Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia

✍ Mario Tiribelli, Roberto Latagliata, Luigiana Luciano… 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 143 KB

First line treatment of chronic phase ch

First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate

✍ Eskazan, Ahmet Emre; Ayer, Mesut; Kantarcioglu, Bulent; Arica, Deniz; Demirel, N 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 55 KB

Population pharmacokinetics of imatinib

Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study

✍ H. Schmidli; B. Peng; G-J. Riviere; R. Capdeville; M. Hensley; I. Gathmann; A. E 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 225 KB

Imatinib produces significantly superior

Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase

✍ Branford, S; Rudzki, Z; Harper, A; Grigg, A; Taylor, K; Durrant, S; Arthur, C; B 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 283 KB